tradingkey.logo

BioLine RX Ltd

BLRX
View Detailed Chart

5.250USD

+1.370+35.31%
Close 05/30, 16:00ETQuotes delayed by 15 min
7.02BMarket Cap
LossP/E TTM

BioLine RX Ltd

5.250

+1.370+35.31%
Intraday
1m
30m
1h
D
W
M
D

Today

+35.31%

5 Days

+43.44%

1 Month

+52.84%

6 Months

-55.81%

Year to Date

-38.67%

1 Year

-82.40%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts
BUY
Current Rating
26.000
Target Price
395.24%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

557
Total
5
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
2
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
28
CRISPR Therapeutics AG
CRSP
28
Regeneron Pharmaceuticals Inc
REGN
28
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(3)
Neutral(1)
Buy(7)
Indicators
Sell(2)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.280
Buy
RSI(14)
84.795
Overbought
STOCH(KDJ)(9,3,3)
62.081
Sell
ATR(14)
0.547
High Vlolatility
CCI(14)
380.481
Overbought
Williams %R
52.940
Neutral
TRIX(12,20)
0.990
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
4.034
Buy
MA10
3.775
Buy
MA20
3.483
Buy
MA50
3.198
Buy
MA100
3.542
Buy
MA200
11.112
Sell

News

More news coming soon, stay tuned...

Company

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Company codeBLRX
CompanyBioLine RX Ltd
CEOMr. Philip Adam (Phil) Serlin
Websitehttps://www.biolinerx.com/
KeyAI